The professionals at Remedy Pharmaceuticals are passionate and committed to the mission of making a difference in the lives of patients and their families faced with devastating CNS-related conditions.

​David M. Geliebter, Executive Chairman, Co-Founder
David is a co-founder of Remedy Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing several businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. Prior to that, David founded Harvard Capital, a financial communications company that was acquired by WPP Group in 1986. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award. CLICK HERE TO EMAIL DAVID

Sven M. Jacobson, MBA, CEO, Co-Founder
Sven is a co-founder of Remedy Pharmaceuticals. He has been the CEO of Remedy since 2007 and serves on the company’s board of directors. He is the inventor of CIRARA’s formulation and the company’s MPD technology. Sven has over 20 years of senior management experience. Sven is a Partner at Carrot Capital Healthcare Ventures and co-founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. Sven was also a co-founder of Access Scientific, which was acquired by Endeavour Capital, as well as Cure Therapeutics, and St. Camillus Medical. He has experience in the neurocritical care, neurology, cardiovascular, orthopedic, and vascular access fields. Sven’s international experience includes prior executive management positions at Leisureplanet (Belgium) and Rennies Travel and Financial Services Group (South Africa), and current board membership of Critical Diagnostics Ltd. (Ireland). Sven received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa. CLICK HERE TO EMAIL SVEN

Thomas W. MacAllister, JD, PhD, Vice President of Research and Development, and General Counsel
Tom is a pharmaceutical executive with a PhD in molecular biology and over 25 years of experience including business development, drug discovery, preclinical and clinical development, regulatory strategy, intellectual property acquisition and enforcement, as well as commercialization. An expert in Phase 3 study design and implementation, Tom has previously assembled and led a team that took a program for severe traumatic brain injury from concept through completion of Phase 3 clinical trials. He has recently held the positions of CEO Argentum Pharmaceuticals, LLC; Chief Development Officer, Besins Healthcare SA; and President & CEO, BHR Pharma LLC. He is an attorney licensed to practice law in the Commonwealth of Virginia, the District of Columbia and before the United States Patent & Trademark Office. CLICK HERE TO EMAIL TOM

Ann C. Tunstall, PhD, Vice President of Regulatory And Clinical Operations
Ann has worked as a regulatory and clinical professional in the healthcare industry for more than 25 years, identifying and implementing effective regulatory and clinical development strategies for novel and repositioned pharmaceuticals and combination products. Her experience covers a wide range of therapeutic areas, with a focus on neurological indications. She started her career as a research and development scientist. After several years she moved into regulatory and clinical consulting, and worked for a number of Washington, DC-based healthcare consulting companies, most recently for SciLucent LLC. In this role she has routinely prepared successful pre-IND, IND and marketing applications to the U.S. Food and Drug Administration and other regulatory authorities, as well as clinical protocols, study reports, and other regulatory and study-related documents. She has assisted companies in directing and managing clinical trial programs from initial Phase 1 through pivotal Phase 3 trials. Ann has also served as the director of a Midwest clinical research institute and Director of Clinical Development for a healthcare start-up. Ann has a Ph.D. in Biomedical Engineering from the University of Texas Southwestern Medical Center, an M.S. in Material Science from Duke University, and a B.S. in Biomedical Engineering from Duke University. CLICK HERE TO EMAIL ANN

Enda F. Anatole, Office Assistant
Enda was graduated with a Bachelors Degree in Human Resource Management from Baruch College in 2013. Prior to joining Remedy she performed administrative duties for Carrot Capital (an investor in Remedy) and Andrew Davidson and Company. CLICK HERE TO EMAIL ENDA

BOARD OF DIRECTORS
​
In addition to board members David M. Geliebter and Sven M. Jacobson (see management above), the board includes Roger Ulrich and J. Marc Simard.

Roger Ulrich
Roger has over three decades of successful drug discovery and development experience. He co-founded Calistoga Pharmaceuticals, which was acquired by Gilead Sciences in 2011 in a transaction valued at up to $600 million. Roger left Gilead in 2012 to help build Acerta Pharma as a member of the Board and as acting Chief Scientific Officer. In February 2016, AstraZeneca acquired a 55% share of Acerta Pharma for $4 billion with an option to purchase the remainder of the company for $3 billion. Prior to Acerta and Calistoga, Roger was senior scientific director with Merck Research Laboratories-Rosetta Inpharmatics, and before that held various scientific and leadership positions within the pharmaceutical industry including Abbott Laboratories, Pharmacia-Upjohn and The Upjohn Company, now part of Pfizer.

J. Marc Simard, M.D., Ph.D. (Scientific Founder)
Marc is Professor of Neurosurgery, Pathology and Physiology at the University of Maryland School of Medicine. He is a board-certified clinical neurosurgeon with an active practice, specializing in vascular neurosurgery, which includes the surgery and management of patients with stroke, subarachnoid hemorrhage and other vascular lesions of the brain. He also serves as chief of Neurological Surgery at the Baltimore Veteran's Affairs Medical Center. Marc is an experienced investigative scientist who is responsible for the original discovery of the Sur1-Trpm4 channel (previously, the Sur1-regulated NCCa-ATP channel), and for initiating the work showing involvement of the channel in acute diseases of the CNS. His work on the Sur1-Trpm4 channel has led to the award of 21 US and international patents, as well as filings for several others.

SPECIAL ADVISORS TO THE BOARD

David Epstein
David spent two-and-a-half decades at Swiss-based Novartis, most recently as Division Head and CEO of the Pharmaceuticals business.  Previously, he started and led Novartis' Oncology and Molecular Diagnostics units.  Under his leadership the Oncology business grew to number two in the world.  David has more than 20 years of extensive drug development, deal making, commercialization and people leadership experience on a global scale. Over the course of his career he lead the development and commercialization of over 30 new molecular entities including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Early in his career, David was an Associate in the Strategy Practice of the consulting firm Booz, Allen and Hamilton. He was recently named by Fierce Biotech to be among "The 25 most influential in biopharma."

Edgar S. Woolard
Ed is a special advisor to Remedy. Mr. Woolard is the former Chairman and Chief Executive Officer of DuPont. He spent four decades with DuPont, before retiring in 1997. As highlighted in Fortune magazine’s 2012 article, “50 Greatest Business Decisions of All Time,” it was Ed, as newly appointed Chairman of the Board of Apple who, in 1997, spearheaded the decision by the board to fire then-CEO Gil Amelio and bring Steve Jobs back to the company, thus saving Apple from likely bankruptcy. Ed is a former director of the New York Stock Exchange Inc., Telex Communications Inc., Citigroup Inc., IBM, Bell Atlantic Delaware, and Apple. He is also a former Chairman of the Business Council.

Charles A. Mele
Charles is a special advisor to Remedy. He currently serves as Special Counsel to the Chairman of WebMD Health Corp. He served as Executive Vice President and General Counsel of HLTH Corporation and its predecessors until its merger into WebMD in 2009. HLTH was the parent company of WebMD, Emdeon Business Services, Medical Manager, ViPs, Inc. and Porex Technologies Corp. Prior to that, from 1986 to 2001 Mr. Mele served as the Executive Vice President and General Counsel of Medical Manager Corp. and its predecessor, Synetic, Inc. He was also Executive Vice President and General Counsel of Medco Containment Services, Inc. from its inception until its acquisition by Merck in 1993. He has served as a Director of Medco, Synetic, CareInsite, Medical Manager, Group One Software and COMNET Corp.